[Response to vaccination against the etiologic agent of viral hepatitis B (HBV) in a population at risk].
We report the results of the vaccinations against hepatitis B carried out with vaccine H-B-VAX of the commercial firm (Merck Sharp and Dohme), on 102 U.S.L. 32 hospital workers in Portomaggiore (Ferrara, Italy). The vaccine rendered 92% of the subjects inoculated immune and the incidence of secondary effects was low.
Lavezzi
M
M
Laboratorio di analisi chimico-cliniche e microbiologiche, U.S.L. 32 Emilia Romagna, Portomaggiore, Ferrara.
Donati
A
A
Davi
D
D
Carpanelli
M C
MC
Farinelli
S
S
Soracco
E
E
D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines
Risposta alla vaccinazione contro l'agente eziologico dell'epatite virale B (HBV) in una popolazione a rischio.